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1.1. Diagnostic strategies
The widespread application of specialist clinics for early eval-
uation of patients with chest pain has focused attention on
the effectiveness of diagnostic testing. In a study of nearly
400,000 patients with suspected coronary artery disease, the
diagnostic yield of cardiac catheterisation was only 37.6%,
leading to calls for better strategies for risk stratiﬁcation.1 As
pointed out in correspondence, the low yield was probably
due to veriﬁcation bias, itself a consequence of basing referral
decisions in low-risk populations on non-invasive tests such as
exercise ECG.2 Similar considerations prompted the NICE
guideline group to recommend a more selective approach to
non-invasive testing based on a careful clinical assessment of
disease probability in patients presenting with stable chest
pain.3 For those with unequivocal histories at the extremes
of diagnostic probability (<10% or >90%) no diagnostic
tests were considered necessary, while for patients with a high
probability of disease (60–90%) invasive angiography without
prior ischaemia testing was recommended. The NICE call for
CT calcium scoring in patients with a low (10–30%) probabil-
ity of disease generated greatest concern, particularly after a
report that 19% of patients without coronary calciﬁcation––
who would have been ruled out for angina in the NICE algo-
rithm––had obstructive (>50% stenosis) disease.4 However,
the population referred for angiography in this study had a
high pre-test probability of disease and in lower-risk popula-
tions CT calcium scoring retains a high diagnostic sensitivity.5
NICE recommendations were driven largely by cost-effective-
ness analysis but whether they will improve the diagnostic yield
of cardiac catheterisation remains to be seen.
1.2. Circulating biomarkers in stable angina
The clinical role of circulating biomarkers for the diagnosis of
obstructive coronary artery disease in patients with suspected
angina has yet to be deﬁned. In one study, blood samples for
the N-terminal fragment of the prohormone brain natriuretic
peptide (NT-proBNP) and various inﬂammatory markers were
obtained in 243 patients before myocardial perfusion imaging.
OnlyNT-proBNPproved signiﬁcantly diagnostic, a cut-off con-centration <25 ng/l predicting a normal perfusion scan with a
negative predictive value>95%.6 Similarly, in an angiographic
study of 848 men and women with clinically suspected coronary
artery disease, NT-proBNP performed better than high-sensi-
tivity C-reactive protein (hsCRP) and c-glutamyltransferase,
showing signiﬁcant association with three-vessel coronary ar-
tery disease, but it did not add to the predictive value of tradi-
tional cardiovascular risk factors. The authors were forced to
conclude that it was of limited incremental value as a diagnostic
tool.7 The prognostic application of circulating biomarkers in
stable coronary artery disease has also been disappointing. In
a meta-analysis of 83 prospective studies reporting the associa-
tion of CRPwith death and non-fatal cardiovascular events, the
authors found that the quality of the studies was so poor (only
two reported a measure of discrimination), with evidence of
reporting bias and publication bias, that they were unable to
make clinical practice recommendations.8 Nevertheless, the
data suggested that CRPmeasurements are unlikely to add any-
thing to the prognostic discrimination achieved by considering
blood pressure and other clinical factors in this patient group.
In another study it was concluded that conventional clinical
information provided an effective means of risk-stratifying
patients with stable coronary disease awaiting coronary bypass
surgery and that additional prognostic information from CRP,
measured singly or in combination with other biomarkers, was
unlikely to be cost-effective.91.3. Medical treatment of angina
Themedical treatment of angina has been the subject of renewed
interest, because of the availability of new treatments such as
ivabradine and ranolazine, and also because of the recognition
that it can compete favourably with revascularisation in many
patients, both for controlling symptoms and for improving
prognosis. Thus, COURAGE showed that in patients receiving
optimal medical treatment (aspirin, b blocker and statin, plus
ACE inhibitor as indicated), percutaneous coronary interven-
tion (PCI) does not improve cardiovascular outcomes and incre-
mental beneﬁts of PCI in quality of life disappear by
36 months.10,11 More recent meta-analyses of trials that have
randomised patients with stable angina to PCI or medical treat-
ment have come to similar conclusions.12,13 This has led guide-
line groups to recommend optimal medical treatment for the
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served principally for patients whose symptoms are not satisfac-
torily controlled.14
1.4. Prognosis of angina
From the early Framingham ﬁnding that angina has ‘a mortal-
ity surprisingly close to that which follows the post-hospital
phase of myocardial infarction’15 to the trialists’ assertions
that ‘cardiovascular risk (is) reduced to normal levels with
contemporary therapy’,16 we now appear to have gone full cir-
cle with two recent outcome studies for patients with angina.
The ﬁrst included 1609 adults with ischaemic heart disease
who were identiﬁed in primary care and were not therefore,
prone to the selection bias that affects secondary care co-
horts.17 The investigators found the hazards of all-cause and
coronary death in patients with angina alone compared with
patients who had had previous myocardial infarction were
0.73 (95% CI 0.55–0.98) and 0.65 (0.44–0.98), respectively.
Although statistically signiﬁcant at the p< 0.05 level these
differences were not signiﬁcant at the p< 0.01 level suggested
as appropriate for observational research. The investigators
also found that physical functioning was consistently lower
among those with angina alone. In the second study, the same
group examined the prognosis of 1785 patients with angina as
a ﬁrst manifestation of ischaemic heart disease.18 Within
5 years, 116 (6.5%) had an acute myocardial infarction, and
175 (9.8%) died. Male sex and each year of increasing age
were both associated with increased HRs for acute myocardial
infarction (2.01 (1.35–2.97) and 1.04 (1.02–1.06), respectively)
and all-cause mortality (1.82 (1.33–2.49) and 1.09 (1.07–1.11),
respectively). An important ﬁnding was that an acute myocar-
dial infarction after the index episode of angina greatly in-
creased the risk of subsequent death. The authors concluded
that appropriate control of risk factors and optimal use of pre-
ventive medical treatments should be aggressively pursued in
patients with angina who represent a high-risk group in pri-
mary care.2. Interventional management of stable coronary artery disease
2.1. Clinical trials
Expectations that COURAGE would lead to changes in the
management of stable angina, with renewed emphasis on opti-
mal medical treatment (OMT) as the primary strategy,19 have
yet to be fulﬁlled, raising questions about how well informed
patients are about the risks and beneﬁts of PCI.20 These ques-
tions have been ampliﬁed by recent studies showing that PCI is
recommended rather than coronary artery bypass grafting
(CABG) substantially more often than indicated by interna-
tional guidelines, and fulﬁls the US societies’ criteria for
appropriateness in only 50.4% of cases.21,22 Rates of PCI in
the USA have shown no tendency to decline since the publica-
tion of COURAGE23 and a majority of patients are not being
treated with OMT. In a large study of elective PCI procedures,
rates of OMT were only 43.5% in 19 months before the publi-
cation of COURAGE and 44.7%, in the 24 months after-
wards, conﬁrming that COURAGE has not yet had a
palpable effect on interventional practice.24Notable among recent reports from other PCI trials are the
10-year follow-up data from MASS II and the results of the
STICH trial. MASS II randomised 611 patients with angina,
multivessel coronary artery disease and preserved left ventric-
ular (LV) function to initial strategies of medical treatment or
PCI or CABG.25 The study was underpowered for the primary
end point of total mortality, Q-wave myocardial infarction, or
refractory angina needing revascularisation, which occurred
less frequently in the CABG group than in the PCI and med-
ical treatment groups (33%, 42% and 59%, respectively).
MASS II excluded patients with signiﬁcant left main stem dis-
ease, and total mortality was similar in all three groups. Nev-
ertheless, the ﬁndings bear comparison with those reported in
the early randomised trials of CABG versus medical treat-
ment26 where patients with multivessel disease who were ran-
domised to CABG survived longer than those randomised to
medical treatment.
STICH also has raised some doubts about the contempo-
rary validity of those early randomised trials. In STICH 1212
patients with multivessel disease and severe impairment of left
ventricular function (ejection fraction < 35%) were random-
ised to coronary artery bypass surgery or medical treatment,
to test whether surgical revascularisation would improve sur-
vival in this high-risk group with ischaemic left ventricular dys-
function.27 After nearly 5-years’ follow-up all-cause mortality
(the primary end point) was similar between the groups, both
in the main trial cohort and in a subgroup with demonstrable
myocardial viability.28 STICH conﬁrms earlier reports29 that
the beneﬁts of revascularisation in patients with ischaemic car-
diomyopathy may have been exaggerated, even in patients with
demonstrable viability. As the editorialist commented, contem-
porary medical treatment should not be underestimated in the
management of severe coronary artery disease.30
Meanwhile, further trials of PCI versus CABG in selected
groups with left main stem disease have been consistent in
favouring CABG, based almost exclusively on lower rates of
repeated revascularisation compared with PCI.31–33 None of
these trials showed signiﬁcant mortality differences between
the two revascularisation strategies, making PCI an option
for those patients unwilling to undergo surgery and prepared
to accept further interventional procedures as necessary. The
SYNTAX trial has already identiﬁed PCI as a reasonable
strategy for symptomatic multivessel disease, particularly if
the SYNTAX score is low (622) when cardiovascular end
points at 3 years are comparable to those for CABG, and this
is reinforced by comparable quality-of-life outcomes.34–36
More recently, a prespeciﬁed subgroup analysis of the
ARTS-II registry has reported comparable outcomes for pa-
tients with multivessel disease involving the proximal left ante-
rior descending coronary artery treated with either sirolimus-
eluting stents (SES) or CABG.37 These comparisons of PCI
versus CABG in high-risk disease and medical treatment
versus CABG in ischaemic cardiomyopathy begin to erode
conﬁdence in the long-held view that surgery is the most
appropriate treatment option in such patients.
2.2. Procedural factors
2.2.1. Radial vs femoral access
Debate about the merits of radial versus femoral access for
interventional procedures has not been resolved by RIVAL,
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comes.38 Among 7021 patients with acute coronary syndrome
undergoing cardiac catheterisation with a view to intervention,
the primary outcome (a composite of death, myocardial infarc-
tion, stroke or non-CABG-related bleeding at 30 days) oc-
curred in similar proportions of radial (3.7%) and femoral
(4.0%) access groups. The marginal difference in favour of
radial access was driven by a trend towards lower bleeding
rates at 30 days (0.7% versus 0.9%), associated with signiﬁ-
cantly lower rates of access site complications, including large
haematomas and pseudoaneurysms. Smaller studies39 have re-
ported less bleeding with radial access which, coupled with ear-
lier mobilisation, has encouraged its adoption in many
European centres. Femoral access, however, is still preferred
by many operators because access is more predictable, proce-
dure times may be shorter and radiation exposure lower than
with the radial approach.40,41 Ultimately, it seems, institu-
tional experience is a major determinant of procedural success,
high-volume radial centres in RIVAL recording the lowest
hazard of the primary outcome.
2.2.2. Pressure wire
Pressure wire measurement of fractional ﬂow reserve (FFR) is
now widely used by interventionists for per-procedural assess-
ment of the functional signiﬁcance of coronary stenoses. In the
FAME study 1005 patients with multivessel coronary artery
disease undergoing drug-eluting stent (DES) implantation
were randomised to procedures guided by angiography alone
or by angiography plus FFR measurement, values <0.80 pro-
viding indication for stenting.42 In the FFR group, the number
of stents per patient (1.9 ± 1.3 versus 2.7 ± 1.2) and the pri-
mary end point of death, non-fatal myocardial infarction or
target vessel revascularisation at 1 year (13.2% versus
18.3%) were both signiﬁcantly lower than for the angiography
group. Beneﬁts were largely sustained at 2 years43 and evidence
of cost-effectiveness44 completes the case in favour of FFR-
guided PCI in multivessel procedures.
2.2.3. Bifurcation PCI
Debate surrounding bifurcation PCI has been largely resolved
by studies showing that simple stenting of the main branch––
with ‘provisional’ stenting of the side branch only if ﬂow be-
comes compromised––is better than strategies that involve
complex stenting of both limbs of the bifurcation. A recent
meta-analysis of randomised trials has conﬁrmed superiority
of the simple stenting strategy which yields better results for
in-hospital and late myocardial infarction and similar rates
of restenosis and target vessel revascularisation compared with
the complex strategy.45 Further reﬁnement of the simple stent-
ing strategy has now been tested by randomising 477 patients
either to ﬁnal kissing balloon inﬂation or to no-ﬁnal kissing
balloon inﬂation.46 Final kissing balloon inﬂation was associ-
ated with a signiﬁcantly lower rate of angiographic side branch
restenosis (8% versus 15%) at 6 months compared with no-
ﬁnal kissing balloon inﬂation, although rates of the primary
end point––cardiac death, myocardial infarction, stent throm-
bosis, or target-lesion revascularisation––were similar (2.1%
versus 2.5%). The data, therefore, do not provide a compelling
argument for ﬁnal kissing balloon inﬂation after simple birfur-
cation stenting, although the strategy does seem to provide
some protection against side branch restenosis.2.2.4. LV support devices
Intra-aortic balloon pump support in high-risk PCI is widely
recommended, but a recent randomised trial in 301 patients
with severe LV dysfunction (ejection fraction 6 30%) and ad-
vanced coronary artery disease found no evidence of beneﬁt.47
Rates of in-hospital major adverse cardiac events were similar
with (15.2%) or without (16.0%) the intra-aortic balloon
pump, arguing against its elective use in this group of patients.
Alternative methods of circulatory support during PCI are
now being investigated and registry data for the Impella 2.5
percutaneous LV assist device conﬁrm that it can be safely
positioned across the aortic valve from the femoral approach
and supply ﬂow rates of up to 2.5 l/min during interventional
procedures.48 These promising data distinguish the Impella
from most other LV assist devices, which require surgical
deployment and have no role in the catheter laboratory.49
2.3. Complications
2.3.1. Acute kidney injury
Contrast-induced acute kidney injury (AKI) is a well-recogni-
sed complication of angiographic procedures, and a recent
Canadian study shows that it has important association with
adverse long-term outcomes.50 Among 14,782 adults undergo-
ing cardiac catheterisation, the adjusted risk of death during a
median 19.7 months’ follow-up increased progressively with
the post-procedural severity of AKI––patients with stage 2 or
3 AKI during the ﬁrst 7 days after catheterisation having
nearly four times the hazard of death compared with patients
with no AKI. Risks of subsequent hospitalisations for heart
failure also increased. Interestingly, AKI has been reported
less commonly with catheterisation using the radial approach
compared with the femoral approach.51 Pre-hydration may
be protective in high-risk individuals, particularly people with
diabetes, but no other speciﬁc treatments have shown unequiv-
ocal beneﬁt.
2.3.2. Bleeding
Peri-procedural bleeding, associated with adverse outcomes
after PCI, has declined notably in recent years.52 Radial access
has probably contributed (see above) but other bleeding avoid-
ance strategies have been emphasised in a study of 1,522,935 pa-
tients entered in the National Cardiovascular Data Registry
CathPCIRegistry.53 The study showed that vascular closure de-
vices and bivalirudin therapy together were associated with a
reduction of bleeding events from 2.8% to 0.9%, yet these strat-
egies were used least often in patients with a high pre-procedural
risk of bleeding assessed with theNational Cardiovascular Data
Registry bleeding risk model.54 Based on these ﬁndings it seems
clear that there remains considerable scope for improving the
safety of PCI by pre-procedural identiﬁcation of patients with
most to gain from individualised bleeding avoidance strategies.
2.3.3. Myocardial injury
Myocardial injury during PCI is common and a recent meta-
analysis of 15 studies embracing 7578 patients found tropo-
nin elevation in 28.7% of procedures.55 Any level of raised
troponin was associated with an increased risk of cardiovas-
cular events and for those with myocardial infarction accord-
ing to the universal deﬁnition56 the OR for major adverse
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dence of peri-procedural myocardial injury has now been
made available from cardiovascular magnetic resonance
imaging, which documented new myocardial hyperenhance-
ment (median mass 5.0 g) in 32% of 152 patients undergoing
PCI. After adjustment for age and sex, these patients had a
3.1-fold (95% CI 1.4–6.8; p= 0.004) higher risk of adverse
outcome than patients without new hyperenhancement.57
These data have enhanced interest in pharmacological and
mechanical interventions directed at protecting the myocar-
dium during elective PCI. High-dose statins show promise
in this regard, and in one study of 668 statin-naı¨ve patients,
peri-procedural myocardial infarction (deﬁned as a CK-MB
elevation >3 upper limit of normal) occurred in 9.5% of
those randomised to a single loading dose of atorvastatin
80 mg, compared with 15.8% in the control group.58 Most
patients should already be taking statins before elective PCI
but for those who are not, these data indicate that pre-proce-
dural loading together with aspirin and clopidogrel is a po-
tential means of enhancing patient safety. Also promising is
remote ischaemic preconditioning, which in a recent random-
ised trial of 242 patients undergoing elective PCI was associ-
ated with reduced troponin I release at 24 h compared with
controls (0.06 versus 0.16 ng/ml; p= 0.040).59 The major ad-
verse cardiac and cerebral event rates at 6 months were also
lower in the remote ischaemic preconditioning group (4 ver-
sus 13 events; p= 0.018). However, this was a small un-
blinded trial and further research is needed before this
inexpensive means of myocardial protection can be recom-
mended in routine clinical practice.2.4. PCI in special groups
2.4.1. Prior radiotherapy
Thoracic radiotherapy in women with breast cancer increases
the long-term risk of cardiovascular death,60 possibly by the
induction of a sustained inﬂammatory response in irradiated
arteries.61 It is also associated with adverse outcomes for cor-
onary stenting, with a HR for all-cause death after 6 years of
4.2 (95% CI 1.8–9.5) compared with people who have not
undergone radiotherapy.622.4.2. Diabetes
CABG has long been the preferred revascularisation strategy
in patients with diabetes and multivessel disease, and the pub-
lication of BARI-2D and CARDia has done little to chal-
lenge this orthodoxy. In BARI-2D, 2368 patients with type
2 diabetes (31% with three-vessel disease) were stratiﬁed as
being appropriate for either PCI or CABG and then random-
ised to contemporary medical treatment or revascularisa-
tion.63 After follow-up for an average of 5.3 years, rates of
all-cause mortality (the primary end point) were similar for
the medical and revascularisation groups, but in the CABG
stratum, patients assigned to revascularisation had lower car-
diovascular event rates (death, myocardial infarction (MI) or
stroke) than patients assigned to medical treatment. How-
ever, the patients in BARI-2D randomised to revascularisa-
tion obtained greater symptomatic beneﬁt than the
medically treated group.64In CARDia, 510 patients with diabetes, 93% of whom
had multivessel disease, were randomised to PCI or CABG.65
The composite rate of all-cause mortality, non-fatal MI, and
non-fatal stroke at 1 year was 13.0% for PCI and 10.5% for
CABG; this difference was not statistically signiﬁcant but the
study was under-powered and non-inferiority for PCI com-
pared with CABG was not conﬁrmed. It is the BARI-2D
ﬁndings, therefore, that generated greater interest by showing
that contemporary medical treatment of diabetic patients
with complex coronary artery disease compares favourably
with revascularisation.
2.5. Outcomes for PCI
Outcomes for PCI (and for CABG) continue to improve.66
Pre-procedural risk factors for adverse outcomes are well de-
ﬁned and include impaired LV function, complex lesion mor-
phology, emergency procedures and diabetes. To this list
may now be added the EuroSCORE, which showed excellent
discrimination for predicting hospital mortality (area under
the receiver operating characteristic curve 0.91 (95% CI
0.86–0.97) in 1173 PCI patients, with the odds of death
increasing as the score rose.67 The EuroSCORE is already val-
idated and widely used to predict surgical risk and the authors
suggest that it is therefore well placed to help cardiologists and
cardiac surgeons individualise the risk proﬁle of patients in or-
der to better select the appropriate revascularisation strategy.
External validation of the EuroSCORE in other PCI cohorts
is now needed before its clinical application can be conﬁdently
recommended. Meanwhile the SYNTAX score, based on spe-
ciﬁc anatomical characteristics of the coronary angiogram, re-
mains the best validated means of anticipating the risks of PCI
and CABG, although its value for predicting 12-month out-
comes is conﬁned to PCI.683. Second-generation DES
DES has produced important reductions in the rates of reste-
nosis compared with bare metal stents (BMS), albeit at in-
creased risk of late stent thrombosis.69 This has provided
impetus for the design of more effective ‘second-generation’
DES that have been the subject of investigation in four recent
trials, all of which were powered for clinical events with a pri-
mary composite end point of cardiac death, myocardial infarc-
tion, or target-vessel revascularisation. The largest of these,
SPIRIT IV, randomised 3687 patients in a 2:1 ratio to receive
second-generation everolimus-eluting stents (EES) or ﬁrst-gen-
eration paclitaxel-eluting stents (PES).70 The study conﬁrmed
superiority of EES over PES for the composite clinical end
point (4.2% versus 6.8%), and also for stent thrombosis
(0.2% versus 0.8%). The single-centre COMPARE trial com-
pared second-generation EES with second-generation PES in
1800 patients and again showed superiority of the EES, which
at 12 months was associated with a 6% incidence of the pri-
mary end point compared with 9% in the PES group.71 The
second-generation zotarolimus-eluting stent (ZES) has been
evaluated against sirolimus-eluting (SORT OUT III, n=
2332) and EES (Resolute All Comers Trial, n= 2292). In
SORT OUT III, ZES proved inferior to SES, with primary
end point rates of 6% versus 3%, a difference sustained at
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end point at 1 year occurred in almost identical (8.2% and
8.3%) proportions of ZES and EES groups, but the ZES group
showed a tendency for more frequent stent thrombosis (2.3%
versus 1.5%) and greater in-stent late lumen loss (0.27 mm ver-
sus 0.19 mm). These observations raise further concerns about
ZES that will not be resolved until the 5-year follow-up data
become available.73 Long-term results of ZES have been
favourable in registries,74 but the results of these four random-
ised trials have ensured that second-generation EES are now
the ﬁrst choice for most interventionists.
Moving beyond the second generation of DES, polymer-free
and biodegradable polymer DES are now entering the clinical
arena. A randomised comparison of rapamycin delivery using
these novel platforms versus conventional (permanent) poly-
mer coated sirolimus-eluting stents, showed comparable safety
and comparable efﬁcacy for the prevention of clinical restenosis
during the 2-year follow-up. However, angiographic surveil-
lance conﬁrmed more sustained neointimal suppression with
the polymer-free rapamycin-eluting stent than with the other
platforms.75 Everolimus delivery by a bioabsorbable stent in
30 patients also produced impressive 2-year outcomes with no
cardiac deaths, ischaemia-driven target lesion revascularisa-
tions, or stent thromboses recorded.76 Interestingly, vasomo-
tion was restored in the stented segment after bioabsorption.
These results will doubtlessly ensure continuing interest in the
development of polymer-free DES.
3.1. Bare metal stents
The advantages offered by DES in the management of coro-
nary artery disease have seen continuing indications for BMS
diminish almost to the point of extinction. The superiority of
DES compared with BMS for primary PCI is driven by signif-
icantly lower rates of target lesion revascularisation, and recent
data show that the beneﬁt is sustained after 3 years (9.4% ver-
sus 15.1%) with no signiﬁcant differences in the rates of death,
reinfarction, or stent thrombosis.77 Current recommendations
are for the preferential use of DES in ST elevation myocardial
infarction, particularly in patients with high-risk features for
restenosis such as long lesions, small vessels, or diabetes.78
The BASKET-PROVE study now also challenges the notion
that BMS have residual indications in large coronary arter-
ies.79 These investigators randomised 2314 patients requiring
3–4 mm diameter coronary stents to receive ﬁrst-generation
SES, second-generation EES, or cobalt-chromium BMS. After
2 years cardiovascular event rates and rates of stent thrombo-
sis were comparable between the three groups, but the rates of
clinically driven target vessel revascularisation were only 4.3%
with SES and 3.7% with EES compared with 10.3% with
BMS. Although cost-effectiveness was not reported, these ﬁnd-
ings conﬁrm that the beneﬁts of DES for safety and protection
against restenosis in small coronary arteries extend to proce-
dures undertaken in larger vessels.
3.2. Paclitaxel-coated balloon
PCI in very small vessels (<3 mm) remains a challenge. Use of
DES has improved safety and longer-term outcomes relative to
BMS,80 and in a randomised trial proved better than the newly
available paclitaxel-coated balloon for restenosis after6 months.81 Nevertheless, a potentially important coronary
application of the paclitaxel-coated balloon for the treatment
of in-stent restenosis has now been identiﬁed. A recent ran-
domised trial in 131 patients with bare metal in-stent restenosis
reported 6-month binary restenosis rates of only 7% for the
drug-coated balloon compared with 20% for a paclitaxel-elut-
ing stent.82 However, longer-term data will be needed. A recent
registry study reported that SES used for the treatment of bare
metal in-stent restenosis exhibited sustained efﬁcacy at 4 years
with a target lesion revascularisation rate of only 11.1%.83
3.3. Antiplatelet therapy
3.3.1. Stent thrombosis
Dual antiplatelet therapy with aspirin and clopidogrel (DAPT)
is considered an essential adjunct to PCI to protect against
stent thrombosis. Guidelines recommend that DAPT is contin-
ued for 12 months in patients who have received a DES to al-
low for complete endothelialisation of the struts, whereupon
treatment can continue with aspirin alone. However, very late
stent thrombosis remains a real concern and has received
attention in a number of recent studies either by evaluating
the potential beneﬁts of prolonging DAPT beyond 12 months
or by up-titrating antiplatelet therapy against the results of
platelet function tests. The impact of prolonged DAPT beyond
12 months has been evaluated in a registry study, which found
no additional protection against death or MI compared with
DAPT for 612 months.84 This was conﬁrmed in a randomised
trial of continuing aspirin and clopidogrel versus monotherapy
with aspirin in 2701 patients who had already received DAPT
for 12 months after PCI.85 At 2-years’ follow-up, rates of MI
and death were similar in the two groups (1.8% versus
1.2%), providing support for the guideline recommendation
to continue DAPT for 12 months after PCI with DES. How-
ever, the importance of strict adherence to DAPT in the ﬁrst
12 months is emphasised by the ﬁnding in another recent study
that patients who delayed ﬁlling their prescription for clopido-
grel after hospital discharge had almost twice the risk of MI or
death compared with those who ﬁlled their prescription on the
day of discharge, even though the median delay was only
3 days.86
3.3.2. High residual platelet reactivity
An alternative approach for protecting against stent thrombo-
sis is to target more aggressive treatment at patients with high
residual platelet reactivity after clopidogrel loading. Such pa-
tients appear to be at signiﬁcantly increased risk of adverse
events, and in a recent study of 215 patients undergoing unpro-
tected left main stem PCI the risk of cardiac death at 1 year
was more than doubled in those with high residual platelet
activity.87 The GRAVITAS investigators have now reported
their randomised comparison of standard dose (75 mg) versus
high-dose (150 mg) clopidogrel after drug-eluting stenting in
2214 patients with high on-treatment platelet reactivity.88
Although high-dose clopidogrel was effective in reducing
platelet reactivity, cardiovascular event rates (death, myocar-
dial infarction, stent thrombosis) after 6 months were identical
at 2.3% in both groups. The failure of aggressive antiplatelet
treatment to reduce event rates in patients with high residual
platelet reactivity was, perhaps, surprising but will not be the
last word on this subject, as other such studies are in progress.
Almanac 2011: Stable coronary artery disease. The national society journals present selected research 65Meanwhile, calls for platelet reactivity monitoring in patients
receiving clopidogrel seem premature.89
A potential mechanism of high residual platelet reactivity in
some patients treated with clopidogrel relates to conversion of
the prodrug to an active metabolite by the hepatic cytochrome
P-450 system. Conversion is genetically determined and is re-
duced in carriers of common loss-of-function CYP alleles,
who show decreased platelet inhibition and a 1.53–3.69
increased risk of cardiovascular events compared with non-car-
riers.90–92 This led to calls for higher clopidogrel dosing in car-
riers of the loss-of-function alleles but this policy has now been
questioned by a study that stratiﬁed patients enrolled in two
large randomised trials of clopidogrel therapy by genotype sta-
tus.93 In neither trial did loss-of-function carrier status affect
the primary composite efﬁcacy outcomes, or safety outcomes
with respect to bleeding. The authors concluded that carriers
of loss-of-function CYP alleles should receive clopidogrel at
currently recommended doses in acute coronary syndromes,
although for atrial ﬁbrillation the conclusion was qualiﬁed by
a need for larger studies. Meanwhile, genotyping of patients
with acute coronary syndromes enrolled in a head-to-head com-
parison of clopidogrel with ticagrelor (PLATO) reported that
the hazard of the primary endpoint was lower for patients ran-
domised to ticagrelor compared with clopidogrel but RR reduc-
tion was unaffected by CYP or ABCB1 (coding for a protein
inﬂuencing clopidogrel absorption) genotype.94 On present evi-
dence, therefore, genetic testing does not appear to be helpful in
determining clopidogrel’s effectiveness in comparison with pla-
cebo or ticagrelor and is unlikely to provide a useful basis for
determining dosing strategies.3.3.3. Drug interaction
Another potential mechanism of high residual platelet reactiv-
ity in some patients receiving platelet inhibitors is an interac-
tion with some proton pump inhibitors (PPIs), which may
reduce clopidogrel’s conversion into its active metabolite by
interfering with the hepatic cytochrome P-450 system and
may also reduce the platelet response to aspirin.95 However,
in a large cohort study event rates among patients discharged
on PPIs were increased independently of whether or not they
were also discharged on clopidogrel, indicating that drug inter-
action was not the responsible mechanism.96 Moreover, the
COGENT trial of 3873 patients receiving DAPT and random-
ised to omeprazole or placebo was reassuring in showing no
difference in the primary cardiovascular end point, a compos-
ite of death from cardiovascular causes, non-fatal myocardial
infarction, revascularisation, or stroke.97 COGENT found
that patients randomised to omeprazole had a signiﬁcantly
lower rate of gastrointestinal bleeding and, given the gastro-
protective effects of PPIs in patients on low-dose aspirin, re-
cently conﬁrmed in the OBERON trial,98 the beneﬁts seem
to outweigh any potential risk related to clopidogrel interac-
tion. Other drugs that have come under recent scrutiny include
calcium channel blockers which, like PPIs, are metabolised by
the hepatic cytochrome P-450 system and have the potential
therefore to interact with clopidogrel. Observational data in
patients taking clopidogrel have shown that high residual
platelet reactivity is more common in those co-prescribed cal-
cium channel blockers than in those who are not,99 and an ear-
lier observational study reported that this may be associated
with a higher cardiovascular event rate 2 years after PCI.100Interpretation of these studies needs to be cautious, however,
and more prospective data are needed, ideally in the form of
randomised trials.4. Coronary artery bypass surgery in stable coronary disease
Among the key technical innovations of the last 15 years have
been off-pump CABG but its potential beneﬁts for myocardial
and cerebral protection have had to be weighed against the
problems of incomplete revascularisation and reports of an in-
creased risk of myocardial infarction and early graft attrition
compared with on-pump procedures. Two randomised trials
have now clariﬁed some of these issues. The ROOBY investi-
gators randomised 2203 patients to on-pump or off-pump
CABG and found no signiﬁcant difference in rates of the 30-
day composite outcome (7.0% versus 5.6%, respectively for
death, reoperation, new mechanical support, cardiac arrest,
coma, stroke, or renal failure).101 After 1 year the same com-
posite was higher for off-pump than for on-pump CABG
(9.9% versus 7.4%, p= 0.04) and graft patency was lower
(82.6% versus 87.8%, p< 0.01) in the 1371 patients who
had follow-up angiography. Meanwhile, a careful assessment
of 12-month cognitive outcomes found no difference between
the groups, although the rate of impairment by either proce-
dure was reassuringly low.102
Shortly after the ROOBY report, the ‘Best Bypass Surgery’
trialists published their results in a higher risk group (Euro-
SCOREP 5, three-vessel disease) of 341 patients randomised
to on-pump or off-pump CABG.103 Again, the composite pri-
mary outcome (all-cause mortality, acute myocardial infarc-
tion, cardiac arrest with successful resuscitation, low cardiac
output syndrome/cardiogenic shock, stroke, and coronary
reintervention) was similar for the on-pump and off-pump
groups (15% and 17%; p= 0.48) and after 3 years all-cause
mortality was signiﬁcantly increased in the off-pump group
(24% versus 15%; HR 1.66, 95% CI 1.02–2.73; p= 0.04).104
These trials have not provided evidence of clinical superiority
for off-pump CABG, although it is premature to consider
abandoning the procedure. Conventional cardiopulmonary
bypass has important deleterious effects that include platelet
and neutrophil activation, consumption of coagulation factors,
complement generation and the release of proinﬂammatory
mediators with the generation of a systemic inﬂammatory re-
sponse. If off-pump surgery cannot deliver better clinical out-
comes it may be prudent to take heed of the editorialist and
consider ‘better-bypass’ in the form of a miniaturised bypass
system.105 This was the subject of a recent meta-analysis which
found that miniaturised cardiopulmonary bypass in compari-
son with conventional cardiopulmonary bypass was associated
with a somewhat lower rate of death (1.1% versus 2.2%, OR
0.58, 95% CI 0.23–1.47, p= 0.25) and stroke (0.2% versus
2.0%, OR 0.25, 95% CI 0.06–1.00, p= 0.05) in the immediate
postoperative period.106 Now needed are larger trials to fur-
ther evaluate the miniaturised cardiopulmonary bypass.References
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